EUCTR2010-018454-13-IT进行中（未招募）不适用
A Phase III, Multicentre, Randomised, Placebo-Controlled, Double Blind Study of the Incidence of Recurring Pulmonary Exacerbations in Cystic Fibrosis Patients using Two Different Doses of Inhaled Nacystelyn - ND
ABORATOIRES SMB S.A.0 个研究点目标入组 552 人开始时间: 2010年6月15日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 552
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients are eligible to be included in the study if they: 1. Have a confirmed diagnosis of CF based on the following: sweat chloride >40 mEq/L and/or genotype with two identifiable mutations consistent with CF and one or more clinical features consistent with CF; 2. Are aged = 12 years; 3. Have FEV1 = 40.0% of predicted; 4. Have experienced at least one treated PE in the previous 12 months prior to Screening; 5. Are on stable rhDNase treatment (2.5 mg via nebuliser once daily) for 3 months before Screening (only for the patients taking rhDNase during the study); 6. Have >80% and <120% compliance during the Run-In period; 7. Have signed a written informed consent form (or assent provided by the parent/guardian) and are willing and able to comply with all study procedures.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be ineligible if one or more of the following statements are applicable: 1. Patient has experienced a treated PE, resolved or unresolved, within 1 month of being screened; 2. Patient has been hospitalised or has had changes in antimicrobial, anti inflammatory, corticosteroids or longacting bronchodilator medications within 2 weeks of randomisation; 3. Patient has been taking any mucolytic drug except rhDNase within 2 weeks of randomisation; 4. Patient has a history of hemoptysis (> 30 cc) within 3 months of randomisation; 5. Patient has participated in another clinical study within 1 month of randomisation; 6. Patient is a smoker of >10 cigarettes/day (or equivalent) or having a smoking history of >10 pack years; 7. Patient has a history of drug, alcohol, or medication abuse within the past 12 months; 8. Patient is pregnant or breast-feeding; 9. Female patient is of child-bearing potential and they or their partner are not using an acceptable form of contraception (defined as the use of an intra-uterine device [IUD], a barrier method with spermicide, condoms, subdermal implants or oral contraceptives); 10. Patient has a history of malignancy within the past 5 years; 11. Patient has a history of lung transplantation, is planning to undergo a lung transplantation during the study period or is currently on a transplantation list; 12. Patient known to have, or at risk of contracting, human immunodeficiency virus (HIV), Hepatitis B, Hepatitis C or tuberculosis; 13. Patients with a know hypersensitivity or intolerance of nacystelyn, acetylcysteine, lysine or lactose; 14. Patient has a condition/abnormality of baseline clinical laboratory results that, in the opinion of the Principal Investigator, would compromise the safety of the patient.
研究者
相似试验
进行中（未招募）
1 期
Effects of a medication being studied (rilematovir) in infants and children and subsequently neonates in the hospital with a respiratory infection due to RSVRespiratory Syncytial VirusMedDRA version: 21.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002023-11-HUJanssen-Cilag International NV737
进行中（未招募）
1 期
Efficacy and safety of adding LX4211 (an investigational oral compound) for patients with Type 1 Diabetes Mellitus (T1D) who have inadequate control of their blood glucose (sugar) levels on insulin alone.Type 1 Diabetes MellitusEUCTR2014-005153-39-LTexicon Pharmaceuticals, Inc.750
进行中（未招募）
1 期
Effects of a medication being studied (rilematovir) in infants and children and subsequently neonates in the hospital with a respiratory infection due to RSVEUCTR2020-002023-11-SEJanssen-Cilag International NV737
进行中（未招募）
1 期
A Study of the Effects of AMG 334 to Prevent Migraine HeadachesEUCTR2014-004464-38-NLAmgen Inc852
进行中（未招募）
1 期
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study)Immunoglobulin A Nephropathy (IgAN)EUCTR2020-003084-26-CZChinook Therapeutics U.S., Inc.320